Use of kallikrein inhibitor for the production of a pharmaceutical for the prophylaxis and therapy of certain diseases
CA 2104636 C · Owner: Eisele, Bernd · Inventors: Eisele, Bernd; Jessel, Andreas; Delvos, Ulrich
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Use of a kallikrein inhibitor for the production of a pharmaceutical for the prophylaxis and therapy of certain diseases The use of C1 inactivator for the production of a pharmaceutical for the prophylaxis and treatment of capillary leak syndrome (generalized extravasation) and circulatory shock (refractory hypotension) in severe burns or scalds in polytrauma, in operations under conditions of extracorporeal circulation in the use of cytokines, endogenous mediators and mediator hybrids and growth factors produced by genetic engineering or capillary leak syndrome and veno-occlusive disease of the liver in therapeutically or prophylactically indicated bone marrow transplantation is described.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 23, 1993 and granted November 11, 2003. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 23, 2013.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 23, 2015.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.